


Substitute for form 1449/PTO & 1449B/PTO Complete if Known

**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(use as many sheets as necessary)

Sheet 1 of 1

**Application** 10/092,919  
**Filing Date** March 8, 2002  
**First Named Inventor** Kjell OLMARKER  
**Examiner Name** Robert B. Mondesi  
**Attorney Docket No.** 1003300-000914



U.S. PATENT DOCUMENTS				
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS										
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS					
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Cited in Spec

NON-PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/RM/	Black L.E. "Pharmacology review of infliximab BLA" - 21-05-1998-found at internet address:
/RM/	<a href="http://www.fda.gov/cder/biologics/review/inflcen082498r4.pdf">http://www.fda.gov/cder/biologics/review/inflcen082498r4.pdf</a>

Examiner Signature	/Robert Mondesi/	Date Considered	05/16/2007
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.